The global Fabry disease treatment market is projected to grow from USD 2.63 billion in 2025 to USD 4.09 billion by 2031, with a CAGR of 7.63%. Growth is driven by expanded screening identifying more patients, advances in gene and mRNA therapies, and sustained enzyme replacement therapy demand. However, high treatment costs remain a significant barrier to patient access, particularly in emerging markets. Asia-Pacific is expected to record the fastest growth at 8.28% CAGR.

Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 newly hired non-executive officers on June 16, 2026, as an inducement for employment. The awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years with 25% vesting annually, contingent on continuous employment.

A class action lawsuit has been filed against Ultragenyx Pharmaceutical for allegedly providing misleading statements about setrusumab's efficacy in treating Osteogenesis Imperfecta. The company claimed the drug would reduce fracture rates, but Phase III Orbit and Cosmic studies failed to achieve statistical significance on primary endpoints. Ultragenyx stock plummeted 42.32% on December 29, 2025, following the announcement of study failures. Investors who purchased shares between August 3, 2023, and December 26, 2025, have until April 6, 2026, to apply as lead plaintiffs.

Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net asset value, resulting in investor losses.

Rosen Law Firm has filed securities class action lawsuits against Ultragenyx Pharmaceutical, Kyndryl Holdings, and Vital Farms, urging investors with significant losses to secure legal counsel before upcoming deadlines. The Ultragenyx case alleges the company made misleading statements about setrusumab's effectiveness in treating Osteogenesis Imperfecta, claiming bone density increases did not correlate to reduced fracture rates as promised.

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding its Phase III Orbit study for setrusumab treatment of Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with basing optimistic interim analysis benchmarks on Phase II results without proper placebo controls, potentially overstating the drug's efficacy. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the class action.

Ultragenyx Pharmaceutical faces a securities fraud class action lawsuit covering the period from August 3, 2023 to December 26, 2025. The lawsuit was triggered by the company's announcement that Phase 3 studies for setrusumab failed to demonstrate statistically significant reduction in fracture rates, resulting in a 42% stock price decline from $34.19 to $19.72. Investors have until April 6, 2026 to request lead plaintiff status.

Pomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to request Lead Plaintiff status.

The Portnoy Law Firm has announced a class action lawsuit on behalf of Ultragenyx Pharmaceutical investors who purchased securities between August 3, 2023 and December 26, 2025. The complaint alleges that Ultragenyx made false and misleading statements regarding its Phase III Orbit study for the drug setrusumab, failing to disclose risks associated with basing interim analysis benchmarks on Phase II results without placebo controls, which could not rule out that observed improvements were due to standard of care improvements and placebo effects rather than the drug's efficacy.

Rosen Law Firm announces securities class action lawsuits against PomDoctor Ltd. and other companies. PomDoctor investors who purchased shares between October 9, 2025 and December 11, 2025 are encouraged to join the class action before the April 7, 2026 deadline. The lawsuit alleges PomDoctor engaged in fraudulent stock promotion schemes involving social media misinformation, insider share dumping, and misleading public statements about the company's business and prospects.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Ultragenyx Pharmaceutical Inc., alleging the company made materially false and misleading statements about its setrusumab drug candidate's ability to reduce fracture rates in osteogenesis imperfecta patients. The lawsuit claims defendants concealed that increased bone density did not correlate with reduced fracture rates, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is April 6, 2026.

Three major securities class action lawsuits have been announced against biopharmaceutical company Ultragenyx Pharmaceutical for allegedly misleading investors about clinical trial results, Driven Brands for misrepresenting financial condition and internal controls, and Super Micro Computer for failing to disclose sales to Chinese companies in violation of export control laws. Investors with substantial losses during the respective class periods are invited to seek lead plaintiff positions.